drugset / Trial / NCT03834220
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
Phase 2
Terminated
63 enrolled
Debiopharm International SA
Caris Life Sciences · collabOptimal Research (Just In Time sites) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to assess the efficacy of Debio 1347 in terms of objective response rate (ORR) in participants with solid tumors harboring fibroblast growth factor receptor (FGFR)1-3 gene fusion/rearrangement.
Timeline
- Start
- 2019-03-22
- Primary completion
- 2020-12-31
- Completion
- 2022-01-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Debio 1347 | Unknown | 80 mg | Oral |